Shanhai Xie, Ph.D. - Publications

Affiliations: 
2002 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Molecular Biology, Oncology, Cell Biology

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

PUBLICATION UPDATES TEMPORARILY DISABLED DURING DATABASE UPDATE, SORRY!

Year Citation  Score
2013 Kwon I, Kato M, Xiang S, Wu L, Theodoropoulos P, Mirzaei H, Han T, Xie S, Corden JL, McKnight SL. Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell. 155: 1049-60. PMID 24267890 DOI: 10.1016/j.cell.2013.10.033  0.36
2012 Han TW, Kato M, Xie S, Wu LC, Mirzaei H, Pei J, Chen M, Xie Y, Allen J, Xiao G, McKnight SL. Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell. 149: 768-79. PMID 22579282 DOI: 10.1016/j.cell.2012.04.016  0.36
2012 Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, Grishin NV, Frantz DE, Schneider JW, Chen S, Li L, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 149: 753-67. PMID 22579281 DOI: 10.1016/j.cell.2012.04.017  0.36
2010 Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM, Becker GL, Huntington P, Goldman SE, Shen CH, Capota M, Britt JK, Kotti T, Ure K, Brat DJ, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 142: 39-51. PMID 20603013 DOI: 10.1016/j.cell.2010.06.018  0.36
2005 Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene. 24: 3246-56. PMID 15735695 DOI: 10.1038/sj.onc.1208500  0.36
2002 Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 21: 7137-46. PMID 12370803 DOI: 10.1038/sj.onc.1205942  0.36
2002 Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Research. 62: 386-90. PMID 11809685  0.36
2001 Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 20: 6188-95. PMID 11593427 DOI: 10.1038/sj.onc.1204834  0.36
1997 Xie S, Price JE, Luca M, Jean D, Ronai Z, Bar-Eli M. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene. 15: 2069-75. PMID 9366524 DOI: 10.1038/sj.onc.1201358  0.36
1996 Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Research. 56: 3426-30. PMID 8758906  0.36
Show low-probability matches.